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ABSTRACT
Hyperbilirubinemia or jaundice has been studied by many researchers because of its diverse causes and
potential for toxicity especially in the neonate but to a lesser extent beyond the neonate as well. Several
studies have been performed on the normal metabolism and metabolic disorders of bilirubin in last decades
of the 20th century. The recent advancement in research and technology facilitated for the researchers to
investigate new horizons of the causes and treatment of neonatal hyperbilirubinemia. This review gives a
brief introduction to hyperbilirubinemia and jaundice and the recent advancement in the treatment of
neonatal hyperbilirubinemia. It reports modifications in the previously used methods and findings of some
newly developed ones. At present, ample literature is available discussing the issues regarding hyper-
bilirubinemia and jaundice, but still more research needs to be done.
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INTRODUCTION
Bilirubin is a naturally occurring organic substance synthesized both in animals and some plants
[1, 2]. In the animal body it is produced as a bile pigment through a natural hemolytic process.
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Bilirubin is synthesized in the reticuloendothelial cells of the spleen and the Kuffer cells of the
liver by routine catabolic degradation of hemoglobin and other hemoproteins including
myoglobin, cytochromes, catalase, and peroxidase pyrrolase. Hemoglobin is oxidized to hem
that is further degraded to iron and porphyrin IXa and porphyrin IX to biliverdin by hem
oxygenase. The green coloured biliverdin is then reduced to yellow coloured bilirubin by bili-
verdin reductase [3–5] (Fig. 1). The bilirubin molecule thus formed consists of a tetrapyrrol
structure with two propionic acid side chains; it remains water-insoluble in free form due to the
formation of six intramolecular hydrogen bonds, gets associated with serum albumin and is
transported to the liver. In hepatocytes, it undergoes the process of conjugation with glucuronic
acid (Fig. 2). The conjugated bilirubin is soluble in water and is excreted through bile into the
small intestine and finally in feces [1, 5–7]. The normal route of synthesis, transportation,
conjugation and excretion of bilirubin is summarized in Fig. 1.
Fig. 1. Illustrations of the normal route of bilirubin metabolism
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BILIRUBIN CONJUGATION AND EXCRETION
At the blood-hepatocyte interface of the sinusoidal membrane, unconjugated bilirubin is
dissociated from albumin and taken up by hepatocytes by facilitated diffusion through organic
anion transporter polypeptides OATP1B1 and OATP1B3 [8, 9]. In hepatocytes, bilirubin binds
to glutathione-S-transferase (GST), also known as ligandin, followed by conjugation with glu-
curonic acid catalyzed by the microsomal bilirubin uridine diphosphate glucuronosyl transferase
(UGT) [10, 11]. Glucuronic acid, due to its low affinity towards UGT, is first converted to
uridine diphosphate glucuronic acid (UDPGA) catalyzed by glucose-6-phosphate dehydroge-
nase (G6PD), then conjugated with the propionic acid residues of bilirubin resulting in the
breakdown of the intramolecular hydrogen bonds and formation of the hydrophilic bilirubin
glucuronides. The water-soluble bilirubin diglucuronides are then transported to bile canaliculi
by ATP-coupled transporters such as the multidrug resistance protein 2 (MRP2) and ATP-
binding cassette C2 (ABCC2). A portion of conjugated bilirubin enters into sinusoidal blood via
an ABCC3, re-up taken by sinusoidal OATP1B1 and OATP1B3 along with unconjugated
bilirubin and excreted again into bile via MRP2 [12].
Once in the canaliculi, more than 98% of the total canalicular bilirubin is transported via the
bile duct to the small intestine, where the canalicular unconjugated and deconjugated bilirubin
(bilirubin glucuronides metabolized back to free bilirubin) is reabsorbed into the enterohepatic
Fig. 2. Mechanism of synthesis and conjugation of bilirubin
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circulation through the intestinal epithelium via ABCC3, binds to albumin and is reuptaken by
hepatic OATP. The reabsorption of conjugated bilirubin is not favored due to its hydrophilic
nature. Conjugated bilirubin is excreted directly in feces along with other breakdown products
and undigested food. However, unconjugated bilirubin is first reduced to urobilinogen and
stercobilinogen by the intestinal microflora and then oxidized to urobilin and stercobilin
pigment, respectively, for their excretion in feces which contribute to the color of stools. The
concentration of urobilinogen may be increased in case of overproduction of bilirubin, reduced
bilirubin clearance by hepatocytes and excessive exposure of bilirubin to intestinal bacteria
[5, 7]. The hepatocellular uptake, the process of conjugation, formation of bilirubin glucuronide,
and canalicular excretion of bilirubin are summarized in Fig. 3.
Fig. 3. Illustrations of hepatocellular uptake, conjugation and excretion of bilirubin
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Hyperbilirubinemia and jaundice
Excess hemolysis, abnormal hepatic uptake of unconjugated bilirubin, abnormalities in conju-
gation process in the case of immature liver, hepatitis, liver cirrhosis and obstruction in the
biliary excretion of conjugated bilirubin are some of the factors responsible for an increase in
serum bilirubin level, a clinical condition known as hyperbilirubinemia. Being insoluble in
water, the unconjugated bilirubin gets deposited in adipose tissues resulting in yellow
pigmentation of skin and eyes, a physiological condition known as jaundice [7, 13, 14].
Depending on the factors responsible for hyperbilirubinemia, jaundice is categorized into
pre-hepatic, hepatic, and post-hepatic jaundice. Pre-hepatic jaundice, also called hemolytic
jaundice is associated with unconjugated hyperbilirubinemia mostly caused by excess he-
molysis and overproduction of bilirubin beyond the conjugating capacity of the liver due to
hyperactivity of hemoxygenase and biliverdin reductase, impaired albumin-bilirubin binding
and defects in the hepatocellular uptake of bilirubin. Hepatic jaundice is associated with both
conjugated and unconjugated hyperbilirubinemia caused by inappropriate conjugation of
bilirubin with glucuronic acid due to low activity of UGT and impaired excretion of conju-
gated bilirubin into bile canaliculi [6, 7, 13, 15]. Post-hepatic jaundice, also known as
obstructive jaundice, cholestatic jaundice or simply cholestasis, is associated with conjugated
hyperbilirubinemia. The major factor responsible for post-hepatic jaundice is the impaired
excretion of conjugated bilirubin due to defects in OATP and MRP2 or the obstruction of the
bile duct [10].
Neonatal Hyperbilirubinemia
The elevated levels of serum bilirubin in neonates is clinically known as neonatal hyper-
bilirubinemia. The high rate of catabolic degradation of heme in fetal erythrocytes, defective
heme oxygenase, defective biliverdin reductase, defective hepatocellular uptake due to poly-
morphism in OAPT1B, relatively low activity of UGT and impaired conjugation of bilirubin due
to immature liver and defective G6PD result in unconjugated hyperbilirubinemia in neonates
[11, 16–18]. In neonates, UGT remains inactive during the foetal life and requires several days
after birth for its induction up to functional levels. UGT activity is sometimes decreased due to
the presence of UGT inhibitors such as pregnanediol, sterols, glucuronidase, non-esterified fatty
acids, and some epidermal growth factors present in the breast milk of the mother resulting in
unconjugated hyperbilirubinemia also known as breast milk jaundice. However, breast milk
jaundice is not limited to UGT inhibitors but may also be associated with some genetic variation
in the UGT1A1 gene [11]. Polymorphism in UGT1A1 has been found to be significantly
associated with the risk of neonatal hyperbilirubinemia in different populations. The variation in
A(TA)6TAA>A(TA)7TAA at nucleotide -53 in the UGT1A1 gene plays a significant role in the
development of neonatal hyperbilirubinemia in Caucasians and some Asian populations, such as
Indians [19] and Malaysians [20]. However, in East-Asian populations, such as Chinese, Jap-
anese and Taiwanese, 211 AA genotype is the main cause of neonatal hyperbilirubinemia,
whereas –53 A(TA)7TAA/A(TA)7T AA seems to have a protective effect against hyper-
bilirubinemia development in neonates fed with breast milk [21]. Breast milk jaundice can be
differentiated from breast feeding jaundice that is characterized by decreased fluid intake and
increased entero-hepatic recirculation of unconjugated and deconjugated bilirubin in breast-fed
babies during the early days of life [22].
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Neonatal cholestasis or cholestatic jaundice is associated with prolonged conjugated
hyperbilirubinemia caused by the abnormalities, infections, and obstruction of the extrahepatic
bile duct. Some antibacterial and antiviral drugs such as fusidic acid, salvianolic acid, Octreotide,
Atazanavir and Indinavir have also been reported to inhibit the hepatocellular catalytic and
transport system and contribute to drug-induced unconjugated and conjugated hyper-
bilirubinemia [23–26].
Hyperbilirubinemia is also characterized by genetic abnormalities in the genes associated
with bilirubin metabolism (Fig. 4). Hyperbilirubinemia associated with UGT activity is linked to
genetic polymorphism in the UGT1A1 gene coding for UGT. Unconjugated and conjugated
hyperbilirubinemia may also be linked to the SLCO1B1 and SLCO1B3 genes coding for solute
carrier organic anion (SLCO) transporter proteins OAPT1B1 and OAPT1B3, respectively. The
reduced activity of these transporter proteins results in elevated levels of conjugated as well as
unconjugated bilirubin in the serum. Polymorphism in the genes coding for the transporter
protein MRP2 involved in the excretion of conjugated bilirubin is also associated with uncon-
jugated and conjugated hyperbilirubinemia [27]. The genetic disorders of bilirubin conjugation
and excretion responsible for hyperbilirubinemia include Gilbert’s Syndrome (GS), Crigler
Najjar Syndrome (CNS), Rotor’s Syndrome (RS) and Dubin-Johnson’s Syndrome (DJS). GS and
CNS are inherited disorders generally characterized by inherited unconjugated hyper-
bilirubinemia associated with decreased conjugation of bilirubin in hepatocytes due to defective
expression of the UGT gene [10, 11, 28]. RS is a rare disorder characterized by low grade
conjugated hyperbilirubinemia due to defective reuptake of conjugated bilirubin by sinusoidal
Fig. 4. Illustrations of the disorders of bilirubin uptake, conjugation and excretion
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transporters OATP1B1 and OATP1B3 [17]. The genetics behind DJS is an autosomal recessive
disorder characterized by inherited conjugated hyperbilirubinemia due to defects in the cana-
licular excretion of conjugated bilirubin by ATP-dependent canalicular transport pumps
ABCC1, ABCC2, ABCC3, and MRP2 [11, 12, 17].
CHEMICAL METHODS FOR DETERMINATION OF BILIRUBIN AND
DIAGNOSIS OF HYPERBILIRUBINEMIA
Diazo method
In circulation, bilirubin is normally found as unconjugated (indirect) bilirubin and conjugated
(direct) bilirubin. Clinically bilirubin is measured as total serum bilirubin and serum direct
bilirubin by a modified diazo method based on Van Den Bergh’s reaction [29]. This method is
based on the formation of the diazo-bilirubin complex by the reaction of bilirubin in the sample
with diazonium ion (formed by the reaction of sulphanilic acid and sodium nitrite) in an
alkaline medium.
sulphanilic acidþ sodiumnitrite→ diazonium ion
bilirubinþ diazonium ion→ azo bilirubinðcolored complexÞ
The green-colored diazo-bilirubin complex has its absorption maximum at 540–560 nm and can
be measured spectrophotometrically. For the determination of serum total bilirubin, caffeine is
added to release the albumin-bound unconjugated bilirubin. The test performed without the
addition of caffeine measures conjugated bilirubin only. The concentration of unconjugated or
indirect bilirubin in the serum can be calculated by the difference between total and direct bilirubin.
Although this is a quick, accurate and widely used clinical method for the diagnosis of
jaundice and hyperbilirubinemia, yet it has some limitations in the field of research. This
method determines the concentration of total and direct bilirubin but not that of the bilirubin
conjugates and its degradation products. It is therefore necessary to find new methods not
limited to bilirubin concentration only but also suitable for the identification and simultaneous
determination of bilirubin conjugates and their degradation products in body fluids.
Peroxidase method
It is an enzymatic method for the determination of free bilirubin but not albumin-bound
bilirubin. The method is based on the principle that horseradish peroxidase catalyzes rapid
oxidation of unbound free bilirubin, whereas albumin-bound bilirubin remains protected
[5, 30]. The method is effective and validated for the determination of unbound free bilirubin in
the serum both in conjugated and unconjugated form and can also be used to determine the
binding affinity of bilirubin to albumin [31]. However, this method is limited to free bilirubin
and it does not measure the degradation products of bilirubin.
Bilirubin oxidase method
This is an enzymatic method used for the determination of total serum bilirubin and direct
bilirubin. The method is based on the enzymatic oxidation of bilirubin to biliverdin catalyzed by
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bilirubin oxidase obtained from Myrothecium verrucaria [32, 33]. In the first step, bilirubin is
oxidized to biliverdin and in the subsequent step biliverdin thus formed is further oxidized to a
purple-colored complex which can be measured spectrophotometrically or amperometrically
using oxygen electrodes [34]. The method is equally effective for the determination of total
bilirubin and direct bilirubin as both are oxidized at the same pH (7.2 and 7.3 respectively). High
performance liquid chromatographic analysis before and after the enzymatic oxidation of bili-
rubin has shown that the method is highly specific with no significant interference by reducing
substances, hemoglobin, and anticoagulants.
Light absorption method
In previous decades researchers have used the light absorption method for the determination of
bilirubin in diluted serum. In normal sera, more than 90% of the yellow color is contributed by
bilirubin, whereas the residual 10% is due to the presence of other substances including caro-
tenes. In hyperbilirubinemic sera, the color of bilirubin dominates the others in the reading.
Bilirubin in serum has its absorption maximum at 453 nm, which can be used for the spec-
trophotometric determination of bilirubin in serum. However, the measurement is impeded by
various interfering factors, mainly oxyhemoglobin, which also has maximal absorption at the
same wavelength. The presence of albumin in the serum is another interfering factor which has
been found to alter the absorption maximum of bilirubin [35].
Non-invasive method
To avoid the pain and other complications of blood sampling, some non-invasive methods have
also been developed for the determination of bilirubin in jaundiced neonates. Transcutaneous
bilinometer, the handheld fiber optic sensing device has been designed for the detection and
measurement of jaundice. The meter first illuminates the skin and subcutaneous tissues and
then measures the intensity of the yellow color of bilirubin spectrophotometrically. The method
is accurate with a significant correlation of results with those obtained by the diazo method [36].
Although the method is quick, economical and easy to handle, yet it is limited to the deter-
mination of total bilirubin level in the skin. Another non-invasive method for determination of
bilirubin is pulse oximetry. This method is based on the principle that the bilirubin in blood
running in the pulse absorbs light at a wavelength different from that absorbed by hemoglobin.
The pulse oximeter determines bilirubin similarly to a bilinometer using light around 480 nm.
However, the results obtained with a transcutaneous bilinometer lose their correlation with the
invasive methods at a level of approximately 10 mg/dL [37].
High-performance liquid chromatography (HPLC)
HPLC is an advanced method used for the identification and determination of bilirubin, its
conjugates and degradation products [38, 39]. It is an advanced and reliable method that has
been proved to be useful for studying the metabolic and degradation products of bilirubin
including bilirubin glucuronides, its photo isomers, as well as products of the radiolysis and
intestinal oxidation of bilirubin [40, 41]. Compared to other methods reported and used for the
determination of serum bilirubin, HPLC is the best method as it gives better separation and
quantification of the components of a mixture. It is more accurate, precise, highly specific and
reliable than the diazo, the direct spectrophotometric and the subcutaneous bilinometric
158 Physiology International 108 (2021) 2, 151–171
methods [42]. Compared to direct spectrophotometry, HPLC is insensitive to interference by
other pigments found in the serum [43]. The individual fractions of various derivatives of
bilirubin produced by metabolic, photolytic and radiolysis treatments can be measured accu-
rately by the use of an internal standard and calibration of the method with standard bilirubin
solution.
Currently used methods of treatment of hyperbilirubinemia
Hyperbilirubinemia is known to cause bilirubin-induced neurological disfunction (BIND) such
as acute encephalopathy in the first few weeks of life, sometimes kernicterus spectrum disorder
(KSD) beyond the neonate with a range of problems including deafness, choreoathetoid cerebral
palsy, and language processing disorder [44, 45]. A high bilirubin/albumin ratio or abnormal
bilirubin-albumin binding due to interference of some drugs leads to cerebral toxicity in neo-
nates. Prolonged hyperbilirubinemia causes irreversible BIND that may lead to death in neo-
nates [46, 47]. An immediate and thorough clearance of bilirubin from the body is necessary by
conversion of the water-insoluble compound to the water-soluble one. Several methods have
been developed to convert hydrophobic unconjugated bilirubin to excretable products for the
management of hyperbilirubinemia.
Phototherapy
Phototherapy involving photo-degradation of bilirubin by white or blue light is the most
commonly used method for the treatment of hyperbilirubinemia. Phototherapy is based on the
photo-oxidation of hydrogen-bonded bilirubin with ZZ conformation, resulting in the break-
down of intramolecular hydrogen bonds and formation of bilirubin photo-isomers with EZ or
ZE conformation. These photo-isomers, being water-soluble, are excreted easily from the body.
However, this treatment method has certain limitations. The time needed under phototherapy is
variable depending on many factors including irradiance of the phototherapy unit, etiology of
the hyperbilirubinemia and exposure of the neonate but can be prolonged in some cases, and
must be discontinued during feeding. There is also a chance of rebinding of bilirubin after
phototherapy and dehydration due to sweating [48, 49].
Chemical treatment
Phenobarbital and phenobarbitone treatment have been proved to be helpful in the management
of unconjugated hyperbilirubinemia caused by the reduced activity of UGT in neonates.
Phenobarbital has been found to induce UGT activity by increasing the expression of the
UGT1A1 gene [50]. However, this treatment takes several days to induce UGT and, therefore, it
is not preferable for the immediate clearance of significant hyperbilirubinemia. This treatment
method is also limited to UGT-dependent unconjugated hyperbilirubinemia and cannot be used
for conjugated hyperbilirubinemia [7]. The oral administration of bilirubin oxidase, an enzyme
that oxidizes bilirubin into less toxic water-soluble products uses its immobilized form to reduce
the toxic effects of bilirubin in the intestines [51]. Oral administration of charcoal and agar
prevents hyperbilirubinemia due to enterohepatic circulation of canalicular unconjugated bili-
rubin and deconjugated bilirubin [7]. However, this treatment is also limited to UGT-dependent
unconjugated hyperbilirubinemia and cannot be used for conjugated hyperbilirubinemia.
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Herbal treatment
Herbal treatment has been a favorable and effective traditional method for the management of
hyperbilirubinemia. A variety of herbs are effective in the treatment of certain liver diseases
including hepatitis and jaundice. Cichorium incubus L., commonly known as chicory is a
traditionally used medicinal plant that possesses several medicinal properties such as antioxi-
dant, anti-inflammatory, anti-ulcerogenic, anti-cancer, anti-bacterial and anti-hepatotoxic ac-
tivities. All parts of this plant have been used traditionally for the treatment of jaundice and
gallstones [52]. Annona muricata (Linn.) is another medicinal plant traditionally used for the
treatment of jaundice. This has been reported to possess hepatoprotective properties. It is
effective in the treatment of carbon tetrachloride- and acetaminophen-induced jaundice in rats
[53]. Agaricus brasiliensis has also been found to be effective in the treatment of phenyl-
hydrazine (PH) induced neonatal jaundice in rats [54]. There are several other medicinal plants
including Prunus domestica, Equisetum debile, Phyllanthus emblica, Punica granatum, and
Raphnus sativus, commonly used for the treatment of jaundice by practitioners [55]. Although
herbal treatment has very few side effects, still it has a slow recovery rate and is not a favorable
method for the treatment of neonatal jaundice.
Exhange transfusion
Blood transfusion or plasmapheresis is another method for the treatment of hyperbilirubinemia.
In exchange transfusion, the infant’s blood is removed in aliquots (15–20 mL) and replaced by
reconstituted blood (one unit of O negative packed red blood cells reconstituted with one unit of
AB fresh frozen plasma to avoid the issues of ABO or Rh incompatibility). Exchange transfusion
results in acute lowering of the infant’s bilirubin level as well as immature red blood cells to avoid
early hemolysis due to transplacental passage of maternal antibodies. Due to adverse effects of
exchange transfusion including thrombocytopenia, hypokalemia, metabolic acidosis, and seizures
as well as to improvements in phototherapy and other treatment methods, this method is not
used commonly for treatment of hyperbilirubinemia. However, this treatment may be preferred
in case if phototherapy fails to significantly reduce the infant’s bilirubin level [56–58].
Plasmapheresis is used for the detoxification of blood by the removal of bilirubin and other
toxic substances. In plasmapheresis, the blood is removed from the hyperbilirubinemic patient
and blood cells are separated from plasma followed by the replacement of plasma with bilirubin-
free human plasma from another source. The blood containing normal bilirubin level is
transfused back into the patient [59–61]. Although this method is useful in the treatment of
hyperbilirubinemia, yet it has chances of contamination and infections.
Liver transplant
Liver transplant has been an option for the treatment of jaundice particularly in inherited
disorders of bilirubin metabolism including CNS and GS, hepatitis and liver carcinoma when all
other remedies are ineffective. A successful transplant of the liver has been reported in two
brothers with CNS-II [62]. The progress and innovations in the method and protocols for the
transplantation of hepatocytes in jaundiced patients have also been reviewed and reported in the
subsequent literature [63]. However, the use of the liver transplantation method is limited due to
its cost, immunological problems, and unavailability of donors.
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Gene replacement therapy
Recently a new method for the treatment of jaundice caused by a genetic disorder in bilirubin
metabolism has been introduced. This treatment method is based on the replacement of genes
responsible for the expression of the proteins involved in bilirubin metabolism. It has been
suggested that the Rotor’s syndrome and Crigler-Najjar’s syndrome may be treated by the
replacement of genes involved in the expression of OATP and UGT [64, 65].
Recent advancements in the treatment of hyperbilirubinemia
Researchers have recently modified the methods previously used for the treatment and manage-
ment of hyperbilirubinemia in neonates. Table 1 presents the findings of some of the latest studies
regarding the new methods of treatment of hyperbilirubinemia and jaundice reported in the last
decade (2011–2020). Phototherapy has been the most effective and commonly used method for the
management of hyperbilirubinemia. However, recent studies have shown that the use of filtered
sunlight, white reflecting curtains, broad-spectrum light, double-sided LED machines, portable LED
phototherapy device and LED light mesh (sleeping bag and blanket) is more effective in reduction
of hyperbilirubinemia in neonates compared to conventional phototherapy [66, 67].
Immunoglobulin therapy has also been an effective method used for increasing the clearance
of bilirubin and minimizing the duration of phototherapy and the need of exchange transfusion
in hemolytic jaundice in ABO-incompatible and Rh-positive neonates [68–70]. However, an
intravenous administration of immunoglobulin (IVIG) during phototherapy by light emitting
diodes (LED) showed no significant dose-dependent increase in bilirubin clearance in ABO-
incompatible neonates [71].
Porphyrin therapy has been used for 3-4 decades as a tool for the management of hyper-
bilirubinemia by inhibiting hemoxygenase [72]. However, supplementation of Zn-protopor-
phyrin during phototherapy significantly inhibited hemoxygenase in newborn mouse model.
The Zn-protoporphyrin-lipid treatment has also been found to be effective in inhibition of
hemoxygenase and reduction of hyperbilirubinemia in newborn mouse models [73]. The
combination of phototherapy and SnMP also effectively reduced the duration and need of
repeated phototherapy for the treatment of hyperbilirubinemia in infants with hemolytic disease
due to Rh incompatibility [74].
A combination of a single dose (50 mg/kg) of clofibrate and phototherapy also significantly
reduced the duration of phototherapy and hospital stay of healthy term hyperbilirubinemic
neonates [75]. Supplementation of a suspension of fenofibrate and vitamin D, E, and C during
white light therapy significantly reduced bilirubin levels and the duration of phototherapy in
neonates [76]. The administration of oxaliplatin in combination with fluro-pyrimidine/folinic
acid and monoclonal antibody, and supplementation of zinc sulfate syrup and Yinzhihuang oral
liquid during phototherapy are also effective for reduction of bilirubin in neonates [77–79].
As discussed earlier, herbal therapy has been a traditionally used method for the treatment of
jaundice. Recently, the combination of herbal therapy with phototherapy has been found to be
more effective than either method used individually. Administration of a 3.75 mg/kg dose of
silymarin (a herbal compound) twice a day effectively reduced the duration of phototherapy for
the management of unconjugated hyperbilirubinemia in neonates [80]. Hand massage and the
combination of traditional Chinese medicine with massage has also been found an effective
option for bilirubin clearance [81, 82].
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Neonates Clofibrate (single dose
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SnMP supplementation effectively prevented the
need for repeated phototherapy for the treatment
of hyperbilirubinemia in infants with hemolytic
disease due to Rh incompatibility.
[74]






The transgenic insertion and expression of
human The OATP1A1 or OATP1B1 gene
enhanced bilirubin clearance and prevented the
onset of Rotor's Syndrome.
[9]
2013 Herbal treatment with
phototherapy
Neonates Silymarin and white
fluorescent light
Administration of 3.75 mg/kg dose of silymarin
twice a day effectively reduced bilirubin levels
and duration of phototherapy for the
management of unconjugated hyperbilirubinemia
in neonates.
[80]
2013 Phototherapy Infants Filtered sunlight Filtered sunlight was found to be safe and
efficacious over conventional phototherapy and
exchange transfusion for the management of
















material Conclusive findings Reference
2015 Phototherapy Neonates White reflecting
curtains
The use of white reflecting curtains was found to
be more effective than conventional phototherapy
in the reduction of bilirubin levels due to high
spectral irradiance and exposure of large surface
area.
[84]
2015 Phototherapy Neonates Broad-spectrum light
(BSL) versus blue
LEDs
Phototherapy with BSL reduced the duration of
treatment compared to that with LED for the
management of hyperbilirubinemia in late
preterm and term infants.
[85]




The ZnPP-lipid treatment effectively inhibited
liver HO and can be used for the treatment of
hyperbilirubinemia in hemolytic disease.
[73]









Treatment with oxaliplatin, FP/FA with and
without monoclonal antibody effectively dropped
the bilirubin level and can be beneficial for the
management of hyperbilirubinemia in patients
with liver dysfunction.
[77]
2017 Chemical treatment Neonates Yinzhihuang oral
liquid
Treatment with Yinzhihuang oral liquid
significantly eliminated the overproduced
bilirubin and may be used as an effective
treatment option for neonatal jaundice.
[86]
2018 Phototherapy Infants Double-sided LED
machine
The use of a double-sided phototherapy machine
enhanced the rate of clearance of serum bilirubin
and decreased the duration of phototherapy and















material Conclusive findings Reference
2018 Chemical treatment
with phototherapy
Neonates Zinc sulfate and blue
LED lamps
Despite the inhibition of enterohepatic
circulation of bilirubin, the zinc salt showed no
significant effect on bilirubin clearance and might
not be effective in the treatment of physiological
jaundice in neonates.
[87]
2018 Exchange transfusion Neonates Exchange transfusion initially decreased the
bilirubin level that was intensified 6 h after the
treatment. The increase in bilirubin levels after
the treatment may be correlated with the
prooxidant-antioxidant balance.
[88]
2018 Phototherapy Neonates Filtered sunlight
versus electric light
Filtered sunlight was found to be safe, efficacious,
inexpensive, and did not interfere with
conventual phototherapy in the treatment of
neonatal jaundice. However, it did not work
better than intensive electric phototherapy for the
management of hyperbilirubinemia in neonates.
[89]
2018 Massage Infants Hand massage Massage treatment is effective in lowering serum
and cutaneous bilirubin levels and increasing








The combination of Chinese medicine washing
and massage increases the excretion of
meconium, reduces the duration of
transformation of meconium and decreases
cutaneous and serum bilirubin. Therefore, it may





















liquid and blue light
Treatment with Yinzhihuang oral liquid in
combination with phototherapy eliminated
bilirubin at a significantly higher rate than
phototherapy alone. This combination was
suggested to be safe and superior to phototherapy
alone for the treatment of neonatal jaundice.
[78]
2019 Home phototherapy Neonates Blue light The home phototherapy method significantly
reduced hospital term admissions and was found
to be cost-effective and well-appreciated by
parents.
[90]
2020 Chemical treatment Neonates Agar and blue light Oral supplementation of agar during
phototherapy effectively reduced bilirubin levels
and the duration of phototherapy, and was
suggested to be safe and effective for fast






E and C, and white
lamps (420–480 nm)
The administration of a single dose of fenofibrate
and vitamin D significantly reduced the bilirubin
level, the duration of phototherapy and stay at
hospital. This treatment method was suggested to
be effective in the treatment of







Neonates LED light mesh
(sleeping bag and
blanket)
The newly developed devices and conventional
phototherapy are equally effective in the
treatment of neonatal jaundice. However, these
devices are helpful in increasing the mother-















material Conclusive findings Reference
2020 Double phototherapy Infants White halogen lamps
or blue fluorescent
tubes
Double phototherapy showed a high rate of
reduction of serum bilirubin level and was
suggested to be more effective than single





Neonates Zinc sulfate syrup and
blue light
The use of zinc sulfate syrup significantly reduced
indirect hyperbilirubinemia in preterm neonates
within 48 h.
[79]
2020 Chemical treatment Pregnant mother (last
month of pregnancy)/
Neonates
Vitamin C Supplementation of vitamin C to mothers in the
last month of pregnancy significantly reduces









Recently, a new method for the treatment of jaundice caused by a genetic disorder in bili-
rubin metabolism has been introduced. This treatment method is based on the replacement of
genes responsible for the expression of the proteins involved in bilirubin metabolism. It has been
suggested that Gilberts syndrome and Crigler-Najjar’s syndrome may be treated by the
replacement of genes involved in the expression of OATP and UGT [64, 65]. In a trial on mice
the transgenic insertion and expression of human OATP1A1 or OATP1B1 enhanced bilirubin
clearance and prevented the onset of Rotor’s Syndrome [9]. However, this method of treatment
is cost-ineffective and immunologically unsafe.
Further suggestions
Although several studies have been performed to find the best methods for the management of
neonatal hyperbilirubinemia, the most convenient, quick, reliable, safe, and time- and cost-
effective method has still not been identified. It is also necessary to optimize the required time
and dosage for significant clearance of bilirubin for each of the previously reported methods to
obtain better results.
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